Protara Q4 net loss $12.8M, cash $170M; ADVANCED-2 12-month data by mid-2025

Protara Therapeutics, Inc.

Cash and equivalents $170.3M as of Dec 31, 2024, funded into 2027 after $100M public offering.
Full year 2024 net loss $44.6M ($2.17/share) vs $40.4M ($3.57/share) in 2023.
ADVANCED-2 trial: 12-month data from evaluable NMIBC patients expected by mid-2025; 72% CR at 6 months reported.
THRIVE-3 registrational trial of IV Choline Chloride to start in 1H 2025; FDA Fast Track granted.
STARBORN-1 interim update for TARA-002 in pediatric LMs expected by end of 1H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.